Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior

被引:53
作者
Hayashi, RJ
Kraus, MD
Patel, AL
Canter, C
Cohen, AH
Hmiel, P
Howard, T
Huddleston, C
Lowell, JA
Mallory, G
Mendeloff, E
Molleston, J
Sweet, S
DeBaun, MR
机构
[1] Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[4] Morehouse Sch Med, Atlanta, GA 30310 USA
[5] Georgia Pediat Pulm Associates, Atlanta, GA USA
[6] Riley Childrens Hosp, Indianapolis, IN USA
关键词
posttransplant lymphoproliferative disease; pediatric; histology;
D O I
10.1097/00043426-200101000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether the morphologic features of posttransplant lymphoproliferative disease (PTLD) correlated to a response to therapy. Patients and Methods: We reviewed our experience with PTLD in the pediatric population. We identified 32 patients with a total of 36 episodes of PTLD. The diagnosis was confirmed by tissue examination and classified according to the degree of monomorphic features of the lesion. Thirty-four of 36 episodes were managed with immunosuppression reduction, and the patients were assessed for their response to this strategy. Chemotherapy was used to treat 10 of 15 patients who had progressive disease, and their subsequent course was also analyzed. Results: Sixteen of 17 (94%) patients with polymorphic morphology responded to immunosuppression reduction compared with only 5 of 17 (29%) patients with monomorphic features (P < 0.001). All of the patients with progressive disease who did not receive additional therapy died. Standard chemotherapy regimens for lymphoma were administered to 10 patients with progressive disease, with a high response rate (90%), durable remissions, and acceptable toxicity. Conclusions: We conclude that the morphologic characteristics of PTLD provide information to potentially help guide treatment strategies in the management of this disease. Standard chemotherapy regimens for malignant lymphoma appear to be a viable treatment option for patients with progressive disease, although further investigation is needed.
引用
收藏
页码:14 / 18
页数:5
相关论文
共 20 条
[1]  
Chadburn A, 1998, CANCER, V82, P1978
[2]   MONOCLONALITY OF LYMPHOPROLIFERATIVE LESIONS IN CARDIAC-TRANSPLANT RECIPIENTS - CLONAL ANALYSIS BASED ON IMMUNOGLOBULIN-GENE REARRANGEMENTS [J].
CLEARY, ML ;
WARNKE, R ;
SKLAR, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (08) :477-482
[3]   EPSTEIN-BARR-VIRUS LYMPHOPROLIFERATIVE DISEASE ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY [J].
COHEN, JI .
MEDICINE, 1991, 70 (02) :137-160
[4]  
DEVITA V T JR, 1990, Journal of the National Cancer Institute Monographs, P19
[5]  
FRIZZERA G, 1981, CANCER RES, V41, P4262
[6]   EFFICACY AND TOXICITY OF 12 COURSES OF ABVD CHEMOTHERAPY FOLLOWED BY LOW-DOSE REGIONAL RADIATION IN ADVANCED HODGKINS-DISEASE IN CHILDREN - A REPORT FROM THE CHILDRENS CANCER STUDY-GROUP [J].
FRYER, CJ ;
HUTCHINSON, RJ ;
KRAILO, M ;
COLLINS, RD ;
CONSTINE, LS ;
HAYS, DM ;
HELLER, RM ;
DAVIS, PC ;
NACHMAN, J ;
OBRIEN, RT ;
ONEILL, JA ;
PRINGLE, KC ;
TRIGG, ME ;
HAMMOND, GD .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :1971-1980
[7]   EPSTEIN-BARR VIRUS-INDUCED B-CELL LYMPHOMA AFTER RENAL-TRANSPLANTATION - ACYCLOVIR THERAPY AND TRANSITION FROM POLYCLONAL TO MONOCLONAL B-CELL PROLIFERATION [J].
HANTO, DW ;
FRIZZERA, G ;
GAJLPECZALSKA, KJ ;
SAKAMOTO, K ;
PURTILO, DT ;
BALFOUR, HH ;
SIMMONS, RL ;
NAJARIAN, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (15) :913-918
[8]  
HANTO DW, 1981, CANCER RES, V41, P4253
[9]  
Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8
[10]  
KNOWLES DM, 1995, BLOOD, V85, P552